Blocking the activity of an essential protein to treat T-cell acute lymphoblastic leukaemia
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Creating innovative new treatments for childhood rhabdomyosarcoma by harnessing the body’s natural defence system
Dr Matthew Blunt aims to create and test immunotherapy treatments for rhabdomyosarcoma that are safer and more effective than chemotherapy.
Looking for early signs on brain MRIs that can predict whether young people with ependymoma will go on to experience cognitive problems
Professor Shivaram Avula will identify markers in the brains of young people with brain tumours that will help predict the development of long-term side effects like learning and memory problems.
A new approach to deliver chemotherapy directly into brain tumours
Professor Rylie Green at Imperial College London will test a device that can deliver chemotherapy directly to brain tumours, sparing healthy cells.
Finding the best way to make two cancer-targeting T cells for the price of one
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Creating advanced models to test new treatments for malignant rhabdoid tumours
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Fighting brain cancer with CAR-T cells: Targeting zombie cells to improve therapy
Dr Ashley Vardon at the University of Birmingham hopes to find a way to effectively fight diffuse midline glioma with new immunotherapies.